EBS
EBS news
Latest 10 stories · newest Nov 3, 2026
EBS
Emergent BioSolutions reports third-quarter 2026 net loss of $32.7 million
Emergent BioSolutions reported Q3 2026 total revenues of $110.0 million but swung to a net loss of $32.7 million. The company also announced a $75 million repurchase of Senior Unsecured Notes and updated its leadership structure.
EBS
Emergent names Frank Vargo interim CFO following Lindahl retirement
CFO Richard Lindahl is retiring, to be succeeded by VP Treasurer Frank Vargo, effective January 1, 2027. Lindahl will serve as senior advisor through March 31, ensuring a smooth leadership transition as part of the company's ongoing transformation plans.
EBS
EBS
Emergent BioSolutions presents at H.C. Wainwright conference
Emergent BioSolutions issued a presentation for its President and CEO at the 28th Annual Global Investment Conference, outlining strategic objectives. The company provided safe harbor statements regarding potential variations in actual results due to factors like US government funding and operationa…
EBS
EBS
EBS
EBS
Emergent receives $52.7M contract modification for ACAM2000 vaccine supply.
Emergent BioSolutions announced a $52.7 million contract modification from the U.S. government to supply ACAM2000 vaccine. This award supports biodefense preparedness and reinforces the company's financial outlook.
EBS
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same EBS feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/EBS/newsSTART FREE